TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 274 participants.

Also called NCT07821008

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 274 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07821008
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07821008. Randomized; double masking; primary purpose treatment. Start 2026-11-24 (anticipated); primary completion 2029-12-14 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study
Acronym
TALISCHER-SAH
Condition
Subarachnoid Hemorrhage, Aneurysmal
Condition
Brain Ischemia
Condition
Endovascular Procedure
Intervention (Drug)
Experimental group: ticagrelor
Intervention (Drug)
Control group: placebo
Lead sponsor
University Hospital, Toulouse (class: other)

Record details

Record id
cardio:ct-nct07821008
Content hash
08dbb10f111c2c8374da497d89c841483c32d0c7dbc9f82f33ed6ba18008e3da